ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has earned a $2.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMNRx …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMNRx in infants with Type I spinal …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that its license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx has received clearance under the Hart-Scott-Rodino …
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced positive results from a Phase 1 study with ISIS-PKKRx.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced today that it has earned a $7 million milestone payment from Biogen Idec related to the advancement of …
(BUSINESS WIRE)–Jan. 9, 2015– Isis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc.